This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

St. Jude Medical Announces Preliminary Third-Party Validation Of Registry Data For Optim-Insulated Defibrillation Leads

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the Population Health Research Institute (PHRI), an academic health science research institute, has completed a preliminary analysis of data received from ongoing prospective registries that monitor the performance of the Durata™ and Riata™ ST Optim implantable cardioverter defibrillator (ICD) leads. The analysis was performed independently by PHRI using St. Jude Medical databases and the results are published beginning on page 240 of the second edition of the 2012 St. Jude Medical Product Performance Report (PPR), released today on

PHRI analyzed data from three actively monitored registries; the OPTIMUM, SCORE and SJ4 Post-Approval registries, all sponsored by St. Jude Medical. The combined data from these registries currently represents 10,987 leads implanted at 293 sites.

The findings from PHRI’s initial analysis of the combined Optim-insulated lead registries, include:
  • 0.06 percent rate of all-cause insulation abrasion (includes all types of abrasion and other mechanical types of insulation damage)
  • 0.31 percent rate of all-cause mechanical failure (includes any insulation abrasion, conductor fracture, failure of a crimp, weld, or bond, or other mechanical failure)

“PHRI conducted this independent analysis of the combined lead registries and found that the rates of insulation abrasion and mechanical failure of Riata ST Optim and Durata leads appear to be very low,” said Dr. John Cairns, professor of Medicine and former dean of Medicine at University of British Columbia in Vancouver. “The strengths of these registries are their prospective designs, the use of pre-specified and standard lead failure definitions, and the adjudication of all outcomes by expert personnel.”

PHRI convened a committee of independent physicians chaired by Dr. John Cairns, an internationally recognized expert in cardiology clinical trials who has no affiliations with the cardiac rhythm management device industry, to perform the analysis. Additional committee members include Dr. Stuart Connolly, professor and director of the Division of Cardiology at McMaster University, Dr. Jeff Healey, associate professor of Cardiology at McMaster University, Dr. Andrew Epstein, professor of Medicine at the University of Pennsylvania and chief of Cardiology at the Philadelphia Veterans Administration Medical Center, and Dr. Christopher Buller, professor of Medicine at The University of Toronto and director of Cardiac Catheterization and Intervention at St. Michael’s Hospital.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs